Crigler-Najjar Syndrome: Causes, Symptoms and Treatment
Crigler-Najjar syndrome is a rare, inherited metabolic disorder in which the liver cannot adequately process bilirubin, leading to severe jaundice and potential brain damage.
Wissenswertes über "Crigler-Najjar Syndrome"
Crigler-Najjar syndrome is a rare, inherited metabolic disorder in which the liver cannot adequately process bilirubin, leading to severe jaundice and potential brain damage.
What is Crigler-Najjar Syndrome?
Crigler-Najjar syndrome is an extremely rare, genetically inherited disorder of bilirubin metabolism. Bilirubin is a byproduct of the breakdown of hemoglobin, the red pigment in blood cells. Under normal circumstances, the liver converts bilirubin into a water-soluble form using the enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1), which is then excreted via bile. In Crigler-Najjar syndrome, this enzyme is severely reduced or completely absent, causing unconjugated (indirect) bilirubin to accumulate in the blood and tissues. The condition was first described in 1952 by physicians John Crigler and Victor Najjar.
Types and Causes
Crigler-Najjar syndrome is divided into two distinct types that differ significantly in severity and prognosis:
Type 1 (Severe Form)
In Type 1, UGT1A1 enzyme activity is completely absent. This is the life-threatening form of the disease. Affected individuals have extremely high blood bilirubin levels (often exceeding 340 µmol/L) and are at high risk of kernicterus (bilirubin-induced brain damage) without treatment. The condition is inherited in an autosomal recessive pattern, meaning both parents must carry a defective copy of the gene for a child to be affected.
Type 2 (Arias Syndrome, Milder Form)
Type 2 (also known as Arias syndrome) is characterized by severely reduced but not entirely absent enzyme activity. Bilirubin levels are elevated but generally lower than in Type 1, and the risk of kernicterus is considerably lower. Many patients with Type 2 respond well to treatment with phenobarbital, which can stimulate the residual enzyme activity.
Symptoms
The primary symptoms of Crigler-Najjar syndrome include:
- Jaundice (icterus): Yellow discoloration of the skin and eyes that appears shortly after birth and persists throughout life.
- Kernicterus: When bilirubin levels are very high (particularly in Type 1), bilirubin can cross the blood-brain barrier and cause neurological damage, including muscle weakness, movement disorders, hearing loss, intellectual disability, or even death.
- Fatigue and general malaise may also occur but are less specific to the condition.
Diagnosis
The diagnosis of Crigler-Najjar syndrome is established through several investigations:
- Blood tests: Detection of markedly elevated bilirubin levels, particularly unconjugated (indirect) bilirubin.
- Liver biopsy or enzyme activity assay: Confirmation of absent or severely reduced UGT1A1 enzyme activity.
- Genetic testing: Identification of mutations in the UGT1A1 gene on chromosome 2.
- Differential diagnosis: Exclusion of other causes of neonatal jaundice, such as hemolytic anemias or Gilbert syndrome, which only causes mild bilirubin elevation.
Treatment
Treatment depends on the type of the condition:
Phototherapy
The mainstay of treatment for Type 1 is intensive phototherapy (light therapy). Patients must spend 10 to 16 hours per day under special blue-spectrum lamps, which convert bilirubin in the skin into an excretable form. This therapy must be continued lifelong and places a significant burden on patients and their families.
Phenobarbital (Type 2)
For Type 2, the medication phenobarbital can enhance residual enzyme activity and reduce bilirubin levels. Many Type 2 patients can be managed effectively with this approach.
Liver Transplantation
The only curative treatment for Type 1 is liver transplantation, since the defect resides in the liver cells. Following a successful transplant, bilirubin levels normalize permanently. However, transplantation carries the standard risks of organ transplant surgery and requires lifelong immunosuppression.
Emerging Therapies
Promising new approaches are being investigated in research, including gene therapy, which aims to deliver a functional UGT1A1 gene into liver cells, and hepatocyte cell transplantation. These therapies are currently in clinical trials.
Prognosis
The prognosis depends strongly on the type. Without treatment, Type 1 is life-threatening in early childhood due to kernicterus. With consistent phototherapy, many patients can survive into adulthood, though the effectiveness of light therapy decreases over time as skin thickness increases. Liver transplantation offers the best long-term prognosis for Type 1 patients. Type 2 carries a significantly better prognosis and is manageable in most cases.
References
- Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics. 1952;10(2):169-180.
- Strauss KA, et al. Crigler-Najjar syndrome type 1: Pathophysiology, natural history, and therapeutic frontier. Hepatology. 2020;71(6):1923-1939. PubMed PMID: 31840268.
- Orphanet: Crigler-Najjar Syndrome. https://www.orpha.net (accessed 2024).
Meistgekaufte Produkte
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryMost read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Crigler-Najjar Syndrome-en